文献速递哮喘呼吸道感染

哮喘表型与COVID-19风险:基于人群的观察性研究

Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

该研究利用电子病历匹配哮喘患者与一般人群,按用药、急性加重史和2型炎症分型,采用Cox回归分析COVID-19结局。共纳入434,348例哮喘患者和748,327例匹配对照。更严重的哮喘与更严重的COVID-19结局相关,但2型炎症无关;COVID-19住院风险与流感或肺炎相似。

要点

  • 规律吸入糖皮质激素联合附加药物治疗或频繁急性加重的哮喘患者,ICU入住或死亡风险显著升高。
  • 特应性和血嗜酸性粒细胞计数与重症COVID-19结局无关。
  • 哮喘患者COVID-19住院风险与流感或肺炎住院风险相似。

核心结论

  • 更严重的哮喘与更严重的COVID-19结局相关,但2型炎症与重症COVID-19结局无关。
  • COVID-19住院风险似乎与流感或肺炎住院风险相似。

研究设计与样本

  • 基于人群的观察性研究,使用电子病历识别哮喘患者并与一般人群匹配。
  • 共纳入434,348例哮喘患者和748,327例匹配患者。
  • 哮喘按用药、急性加重史和2型炎症进行表型分型,采用Cox回归分析COVID-19结局。

主要发现

  • 所有哮喘患者基层诊断COVID-19的风险显著增加。
  • 规律ICS使用(HR 1.27;95%CI 1.01-1.61)、间歇ICS联合附加药物(HR 2.00;95%CI 1.43-2.79)、规律ICS联合附加药物(HR 1.63;95%CI 1.37-1.94)或频繁急性加重(HR 1.82;95%CI 1.34-2.47)与住院显著相关。
  • 仅规律ICS联合附加药物治疗(HR 1.70;95%CI 1.27-2.26)或频繁急性加重(HR 1.66;95%CI 1.03-2.68)的患者ICU入住或死亡风险显著升高。
  • 特应性和血嗜酸性粒细胞计数与重症COVID-19结局无关。

临床怎么用

  • 对规律ICS联合附加药物治疗或频繁急性加重的哮喘患者,应关注其COVID-19重症风险。
  • 哮喘患者COVID-19住院风险与流感或肺炎相似,可参考相应管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Studies have suggested some patients with asthma are at risk of severe coronavirus disease (COVID-19), but they have had limited data on asthma phenotype and have not considered if risks are specific to COVID-19. Objectives: To determine the effect of asthma phenotype on three levels of COVID-19 outcomes. Compare hospitalization rates with influenza and pneumonia. Methods: Electronic medical records were used to identify patients with asthma and match them to the general population. Patient-level data were linked to Public Health England severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test data, hospital, and mortality data. Asthma was phenotyped by medication, exacerbation history, and type 2 inflammation. The risk of each outcome, adjusted for major risk factors, was measured using Cox regression. Measurements and Main Results: A total of 434,348 patients with asthma and 748,327 matched patients were included. All patients with asthma had a significantly increased risk of a General Practice diagnosis of COVID-19. Asthma with regular inhaled corticosteroid (ICS) use (hazard ratio [HR], 1.27; 95% confidence interval [CI], 1.01-1.61), intermittent ICS plus add-on asthma medication use (HR, 2.00; 95% CI, 1.43-2.79), regular ICS plus add-on use (HR, 1.63; 95% CI, 1.37-1.94), or with frequent exacerbations (HR, 1.82; 95% CI, 1.34-2.47) was significantly associated with hospitalization. These phenotypes were significantly associated with influenza and pneumonia hospitalizations. Only patients with regular ICS plus add-on asthma therapy (HR, 1.70; 95% CI, 1.27-2.26) or frequent exacerbations (HR, 1.66; 95% CI, 1.03-2.68) had a significantly higher risk of ICU admission or death. Atopy and blood eosinophil count were not associated with severe COVID-19 outcomes. Conclusions: More severe asthma was associated with more severe COVID-19 outcomes, but type 2 inflammation was not. The risk of COVID-19 hospitalization appeared to be similar to the risk with influenza or pneumonia.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Bloom CI, Cullinan P, Wedzicha JA, et al. Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study. Am J Respir Crit Care Med. 2022. PMID: 34669568. doi:10.1164/rccm.202107-1704OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。